DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Ind-Swift Laboratories Limited — Investor Presentation

NSE 1 hr ago·4 Nov 2026, 6:11 am

Ind-Swift Laboratories

Ind-Swift Laboratories Limited has submitted its investor presentation to the stock exchange. This document outlines the company's current business strategy, financial performance, and future outlook for the upcoming period.

For investors, this update is a key opportunity to understand management's vision and assess the company's direction. It provides insights into operational efficiency and growth plans that may influence the stock's valuation.

Investors should focus on the management's commentary regarding market trends and cost control measures. Monitoring the company's response to industry challenges will be crucial for gauging its competitive position in the pharmaceutical sector.